An Australian marketing company that allows clients to schedule socal media posts has won a temporary court injunction against Facebook and Instagram in a lawsuit alleging a decision to block the startup from their platforms is a misuse of market power.
Citigroup has agreed to refund $3 million to 114 customers that suffered losses stemming from investments in complex financial products, after ASIC raised concerns that some of the customers may have thought they were getting personal rather than general advice.
Generic drug maker Sandoz has secured a retroactive licence to manufacture a cheaper version of top-selling antidepressant Lexapro, the drug at the heart of a long-running patent infringement battle with pharmaceutical giant Lundbeck.
Racing Victoria has dragged fantasy sports gambling company PlayUp to court for allegedly infringing its ‘Best Bets’ trade marks.
An Australian Rugby League Commission rule barring St George Illawarra Dragons forward Jack de Belin from taking the field is “draconian” and “unfair”, a court has heard at the beginnig of a three day trial challenging the ‘no-fault’ rule.
A battle over unpaid fees by a former Mills Oakley client is not over after a judge found the law firm notifed the company of default judgment against it almost a month before winning the judgment.
Wealth manager IOOF has dismissed a shareholder class action lawsuit related to allegations of misconduct aired at the Banking Royal Commission, calling it “speculative and unfounded”.
Two class actions against collapsed engineering firm RCR Tomlinson may be dismissed earlier than expected unless the Supreme Court allows them proceed against a liquidator who has said the failed company is strapped of funds.
The Australian Competition and Consumer Commission has filed Federal Court proceedings against comparison website iSelect for allegedly favouring energy plans offered by preferred retail partners over other, cheaper alternatives.
A judge has denied Mylan’s bid to temporarily block Sun Pharma and Cipla from making generic versions of anti-cholesterol drug Lipidil while it appeals a ruling invalidating several claims of its patents for the drug, citing the “difficulty, complexity and uncertainty” in assessing compensation under an undertaking as to damages in pharmaceutical patent proceedings.